Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer

Nelofer Syed(Hammersmith Hospital), Tim Crook(Bupa Cromwell Hospital), Dominique Koensgen(Brighton and Sussex Medical School), Eleftheria Hatzimichael(Thomas Jefferson University), Sarah P. Blagden(Churchill Hospital), Iain A. McNeish(Imperial College London), Alexander Mustea(University Hospital Bonn), David P. Lovell(St George's, University of London), Peter Schmid(Queen Mary University of London), Jalid Sehouli(Charité - Universitätsmedizin Berlin), Helen M. Coley(University of Surrey), Peter W. Szlosarek(St Bartholomew's Hospital)
Cancer Research
March 15, 2011
10.1158/0008-5472.can-10-2048
Cited by 60

Related Papers

Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k